Trial · NCT01739348
Participant flow32
How many started, completed or left each group, period by period.
1 to 20 of 32
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part I (Base Study) | STARTED | Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II] | 703 | |
| Part I (Base Study) | STARTED | Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II] | 700 | |
| Part I (Base Study) | STARTED | Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II] | 103 | |
| Part I (Base Study) | STARTED | Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II] | 705 | |
| Part I (Base Study) | Treated | Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II] | 702 | |
| Part I (Base Study) | Treated | Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II] | 700 | |
| Part I (Base Study) | Treated | Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II] | 103 | |
| Part I (Base Study) | Treated | Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II] | 705 | |
| Part I (Base Study) | COMPLETED | Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II] | 501 | |
| Part I (Base Study) | COMPLETED | Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II] | 497 | |
| Part I (Base Study) | COMPLETED | Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II] | 77 | |
| Part I (Base Study) | COMPLETED | Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II] | 516 | |
| Part I (Base Study) | NOT COMPLETED | Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II] | 202 | |
| Part I (Base Study) | NOT COMPLETED | Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II] | 203 | |
| Part I (Base Study) | NOT COMPLETED | Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II] | 26 | |
| Part I (Base Study) | NOT COMPLETED | Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II] | 189 | |
| Part II (Extension Study) | STARTED | Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II] | 379 | |
| Part II (Extension Study) | STARTED | Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II] | 366 | |
| Part II (Extension Study) | STARTED | Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II] | 61 | |
| Part II (Extension Study) | STARTED | Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II] | 396 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01739348/flow